Biogen Inc. sees a notable uptick in its stock price following a bullish upgrade from JPMorgan.
Shares of Biogen Inc. (NASDAQ:BIIB) are rising today, gaining 3.22% to close at CA$232.97. This positive momentum follows a significant upgrade from JPMorgan, which has bolstered investor confidence in the biotech company's future prospects.
Advertisement
Biogen Inc
BIIB.US
BIIB.US
Biogen Inc
WealthAwesomeMarket cap
$33.35B
P/E
40.1x
52W high
$230.49
52W low
$138.00
1W change
+2.65%
Beta
0.09
Analyst Price Targets
Based on 35 analysts covering BIIB · as of Oct 12, 2026
Wall Street analysts forecast BIIB stock price to rise 6.0% over the next 12 months.
Consensus
Buy4.11 / 5.00
Avg. Target
C$239.18
+6.0% Upside
Previously C$238.18 on Oct 5, 2026
Current Price
C$225.71
Last close
Analyst Breakdown (35 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BIIB's historical volatility
30-Day Vol
25.4%
Annualized
90-Day Vol
35.2%
Annualized
Trend (90d)
+32.5%
Annualized drift
90d Mean
C$253.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$234.60 | C$214.89 – C$256.12 |
| 60 trading days | C$243.85 | C$215.39 – C$276.07 |
| 90 trading days | C$253.46 | C$217.72 – C$295.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of JPMorgan's upgrade and the potential catalysts in Biogen's pipeline as they evaluate their positions in the stock.
3.22% Increase in Stock Price
Biogen's stock rose by 3.22%, reflecting renewed investor interest following a bullish analyst report.
Bull case
With JPMorgan's upgrade to 'Overweight' and a price target of $300 by December 2027, Biogen is set for potential growth driven by upcoming clinical readouts and a diverse pipeline beyond its Alzheimer's treatment. The company is making strides with its new projects, particularly with Felzartamab, which aims to address kidney transplant complications.
Bear case
Despite the positive upgrade, some concerns linger about Biogen's past revenue declines and the risks tied to its clinical trials, which could affect future stock performance.
Advertisement
JPMorgan's Upgrade Fuels Investor Confidence
JPMorgan recently upgraded Biogen's stock rating from 'Neutral' to 'Overweight', citing a stronger outlook due to several anticipated clinical readouts in 2027. Analyst Chris Schott emphasized that Biogen is evolving beyond its Alzheimer's drug Leqembi, identifying significant opportunities in its pipeline.
Market Reaction and Future Prospects
The market responded positively to the news, with Biogen's shares climbing 3.22% today. Investors are optimistic about the company's potential to deliver accelerated growth as it navigates through its upcoming clinical trials. With a price target set at $300, there is a sense of renewed hope for Biogen's long-term performance, despite lingering concerns about its historical revenue trends.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
